Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 9/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3269099 | 0.91 | CHRM4 (0.43) | CHRM4L3MBTL1CHRM2CHRM1DGAT1 | |
| SCHEMBL3269094 | 0.90 | CKS1B (0.47) | CHRM4TDP1L3MBTL1CKS1BSKP1 | |
| SCHEMBL3269081 | 0.85 | CHRM4 (0.57) | CHRM4TDP1L3MBTL1CHRM2CHRM1 | |
| SCHEMBL3269077 | 0.84 | CHRM4 (0.49) | CHRM4L3MBTL1CHRM2CHRM1 | |
| SCHEMBL3266256 | 0.84 | DEGS1 (0.48) | CHRM4L3MBTL1CHRM2CHRM1 | |
| SCHEMBL3266210 | 0.84 | CHRM4 (0.45) | CHRM4CHRM2CHRM1 | |
| SCHEMBL3265677 | 0.84 | TDO2 (0.51) | CHRM4TDP1L3MBTL1CKS1BSKP1 | |
| SCHEMBL1711018 | 0.84 | CHRM4 (0.57) | CHRM4CKS1BSKP1SKP2CHRM2 | |
| SCHEMBL345122 | 0.84 | CHRM4 (0.43) | CHRM4TDP1CKS1BSKP1SKP2 | |
| SCHEMBL3265618 | 0.83 | CNR1 (0.41) | CHRM4L3MBTL1CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CHRM4 243/4885TDP1 4014/4885L3MBTL1 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.